Remote Monitoring and Virtual Visits

CAPA Framework – IoT and Wearable Devices for Remote Capture

Posted on digi By digi

With the shift towards decentralized clinical trials (DCTs), the use of Internet of Things (IoT) devices and wearable technology has gained widespread acceptance for remote monitoring and real-time data capture. Devices such as smartwatches, biosensors, digital patches, and connected inhalers allow continuous data collection from trial participants outside of traditional clinical settings. However, the integration of these technologies introduces unique compliance risks, especially related to data integrity, validation, patient privacy, and corrective action.
Click to read the full article.

eConsent and Remote Data Collection, Remote Monitoring and Virtual Visits

Handling Missing Remote Data – Compliance Checklist

Posted on digi By digi

Decentralized and hybrid clinical trial models have introduced new complexities in data capture. With participants reporting data via eConsent platforms, wearable devices, mobile apps, or portals, the risk of missing data has increased. Missing data may arise from technical issues, patient non-compliance, data sync failures, or platform errors. Regardless of the cause, such gaps can pose serious threats to data integrity, endpoint reliability, and regulatory compliance.
Click to read the full article.

eConsent and Remote Data Collection, Remote Monitoring and Virtual Visits

When to Use Hybrid Monitoring Approaches: Lessons Learned from Global Audits

Posted on digi By digi

Hybrid monitoring combines traditional onsite visits with remote data oversight, offering a flexible, risk-adaptive approach to trial conduct. The COVID-19 pandemic accelerated its adoption, but as regulatory expectations evolve, sponsors must make deliberate, audit-proof decisions about when and how to use this model. The FDA, EMA, and ICH now recognize hybrid strategies as valid—when properly implemented within a structured, risk-based monitoring plan.
Click to read the full article.

Hybrid Monitoring Models, Remote Monitoring and Virtual Visits

Case Studies on Cost-Benefit Analysis of Hybrid Models and CAPA Solutions

Posted on digi By digi

Hybrid clinical trial monitoring models have emerged as a strategic alternative to traditional monitoring methods, blending remote and onsite oversight. While regulatory authorities such as the FDA and EMA acknowledge their potential, sponsors must justify their use with clear cost-benefit analyses—especially during regulatory audits. This article provides real-world case studies and corrective action/preventive action (CAPA) insights from global trials where hybrid models were deployed.
Click to read the full article.

Hybrid Monitoring Models, Remote Monitoring and Virtual Visits

Transitioning from On-Site to Hybrid Monitoring – CAPA Solutions

Posted on digi By digi

Clinical trial monitoring has traditionally been rooted in on-site verification—frequent CRA visits, paper-based source verification, and physical access to trial data. However, recent shifts in trial decentralization, pandemic constraints, and risk-based oversight have catalyzed a shift toward hybrid monitoring models. These models blend remote access with selective on-site activities, aligning with FDA, EMA, and ICH GCP recommendations for flexible monitoring plans that prioritize critical data and processes.
Click to read the full article.

Hybrid Monitoring Models, Remote Monitoring and Virtual Visits

Building Training CRAs for Hybrid Oversight for Regulatory Compliance

Posted on digi By digi

Hybrid monitoring models—combining both on-site and remote oversight—have redefined the role of Clinical Research Associates (CRAs). Traditional CRA responsibilities focused on physical site visits, source data verification (SDV), and monitoring logs. Today, CRAs must navigate virtual platforms, remote eSource access, risk-based monitoring tools, and data dashboards in addition to periodic site interactions.
Click to read the full article.

Hybrid Monitoring Models, Remote Monitoring and Virtual Visits

FDA-Ready Guide – Hybrid Visit Documentation Requirements

Posted on digi By digi

Hybrid monitoring models combine elements of traditional on-site monitoring with centralized or remote strategies. While this model introduces flexibility and efficiency, it also presents significant challenges in maintaining consistent and compliant documentation. Regulatory authorities such as the FDA, EMA, and MHRA expect complete, contemporaneous, and accurate records regardless of whether a monitoring visit is virtual or in person.
Click to read the full article.

Hybrid Monitoring Models, Remote Monitoring and Virtual Visits